Don’t Worry, Be Happy: Endocannabinoids and Cannabis at the Intersection of Stress and Reward.

Image result for annual review of pharmacology and toxicology

“Cannabis enables and enhances the subjective sense of well-being by stimulating the endocannabinoid system (ECS), which plays a key role in modulating the response to stress, reward, and their interactions.

The recent shift toward legalization of medical or recreational cannabis has renewed interest in investigating the physiological role of the ECS as well as the potential health effects, both adverse and beneficial, of cannabis.

Here we review our current understanding of the ECS and its complex physiological roles.

We discuss the implications of this understanding vis-á-vis the ECS’s modulation of stress and reward and its relevance to mental disorders in which these processes are disrupted (i.e., addiction, depression, posttraumatic stress disorder, schizophrenia), along with the therapeutic potential of strategies to manipulate the ECS for these conditions.”

http://www.ncbi.nlm.nih.gov/pubmed/27618739

Evaluation of Two Commercially Available Cannabidiol Formulations for Use in Electronic Cigarettes.

Image result for Front Pharmacol.

“Since 24 states and the District of Columbia have legalized marijuana in some form, suppliers of legal marijuana have developed Cannabis sativa products for use in electronic cigarettes (e-cigarettes).

Personal battery powered vaporizers, or e-cigarettes, were developed to deliver a nicotine vapor such that smokers could simulate smoking tobacco without the inherent pathology of inhaled tobacco smoke. The liquid formulations used in these devices are comprised of an active ingredient such as nicotine mixed with vegetable glycerin (VG) and/or propylene glycol (PG) and flavorings.

A significant active ingredient of C. sativa, cannabidiol (CBD), has been purported to have anti-convulsant, anti-nociceptive, and anti-psychotic properties. These properties have potential medical therapies such as intervention of addictive behaviors, treatments for epilepsy, management of pain for cancer patients, and treatments for schizophrenia.

However, CBD extracted from C. sativa remains a DEA Schedule I drug since it has not been approved by the FDA for medical purposes.

Two commercially available e-cigarette liquid formulations reported to contain 3.3 mg/mL of CBD as the active ingredient were evaluated. These products are not regulated by the FDA in manufacturing or in labeling of the products and were found to contain 6.5 and 7.6 mg/mL of CBD in VG and PG with a variety of flavoring agents. Presently, while labeled as to content, the quality control of manufacturers and the relative safety of these products is uncertain.”

http://www.ncbi.nlm.nih.gov/pubmed/27621706

pain in Extrapyramidal Neurodegenerative Diseases.

Image result for Clin J Pain.

“Pain is one of the most common non-motor symptoms of Parkinson disease (PD) and other Parkinson plus syndromes, with a major effect on quality of life.

The aims of the study were to examine the prevalence and characteristics of pain in PD and other Parkinson plus syndromes and patient use and response to pain medications.

The most beneficial analgesics were nonsteroidal anti-inflammatory drugs and medical cannabis.”

http://www.ncbi.nlm.nih.gov/pubmed/27623111

A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis.

Image result for journal of pain research

“A randomized, placebo-controlled crossover trial utilizing vaporized cannabis containing placebo and 6.7% and 2.9% delta-9-tetrahydrocannabinol (THC) was performed in 42 subjects with central neuropathic pain related to spinal cord injury and disease.

Dose-dependent improvement in pain score was evident across all pain scale elements.

Plans for future work are outlined to explore the relationship of plasma concentrations with the analgesic response to different cannabinoids.

Such an appraisal of descriptors might contribute to the identification of distinct pathophysiologic mechanisms and, ultimately, the development of mechanism-based treatment approaches for neuropathic pain, a condition that remains difficult to treat.”

http://www.ncbi.nlm.nih.gov/pubmed/27621666

Got Munchies? Estimating the Relationship between Marijuana Use and Body Mass Index.

Image result for J Ment Health Policy Econ

“Although marijuana use is commonly associated with increased appetite and the likelihood of weight gain, research findings in this area are mixed.

Most studies, however, report cross-sectional associations and rarely control for such important predictors as physical activity, socioeconomic status, and alcohol and other drug use.

Results show that daily female marijuana users have a BMI that is approximately 3.1% (p<0.01) lower than that of non-users, whereas daily male users have a BMI that is approximately 2.7% (p<0.01) lower than that of non-users.

 

The present study indicates a negative association between marijuana use and BMI.

Uncovering a negative association between marijuana use and weight status is a valuable contribution to the literature, as this result contradicts those from some previous studies, which were unable to address time-invariant unobserved heterogeneity.”

http://www.ncbi.nlm.nih.gov/pubmed/27572145

“Daily Marijuana Use Linked to Lower BMI”           http://www.livescience.com/56068-daily-marijuana-use-linked-to-lower-bmi.html

“Marijuana Makes You Skinny? New Study Says Pot May Lead To Lower Body Mass Index” http://www.ibtimes.com/marijuana-makes-you-skinny-new-study-says-pot-may-lead-lower-body-mass-index-2414737

“Smoking marijuana can lower your BMI, study finds”  https://www.rawstory.com/2016/09/smoking-marijuana-can-lower-your-bmi-study-finds/

Activation of Cannabinoid Receptor Type II by AM1241 Ameliorates Myocardial Fibrosis via Nrf2-Mediated Inhibition of TGF-β1/Smad3 Pathway in Myocardial Infarction Mice.

Image result for Cell Physiol Biochem

“Myocardial interstitial fibrosis is a major histologic landmark resulting in cardiac dysfunction after myocardial infarction (MI).

Activation of cannabinoid receptor type II (CB2 receptor) have been demonstrated to reduce fibrosis in hepatic cirrhotic rat.

In this study, we aimed to investigate the effects of a CB2 receptor selective agonist AM1241 on myocardial fibrosis post MI in mice.

CONCLUSION:

CB2 receptor agonist AM1241 alleviated myocardial interstitial fibrosis via Nrf2 -mediated down-regulation of TGF-β1/Smad3 pathway, which suggested that CB2 receptor activation might represent a promising target for retarding cardiac fibrosis after MI.”

http://www.ncbi.nlm.nih.gov/pubmed/27614871

Maternal Marijuana Use and Adverse Neonatal Outcomes: A Systematic Review and Meta-analysis.

Image result for Obstet Gynecol.

“To estimate whether marijuana use in pregnancy increases risks for adverse neonatal outcomes and clarify if any increased risk is attributable to marijuana use itself or to confounding factors such as tobacco use.

CONCLUSION:

Maternal marijuana use during pregnancy is not an independent risk factor for adverse neonatal outcomes after adjusting for confounding factors.

Thus, the association between maternal marijuana use and adverse outcomes appears attributable to concomitant tobacco use and other confounding factors.”

http://www.ncbi.nlm.nih.gov/pubmed/27607879

“Using Pot While Pregnant Not Tied to Birth Risks. Smoking marijuana during pregnancy doesn’t appear to increase the risk of preterm birth or other harmful birth outcomes, a new review study suggests.” http://www.livescience.com/56036-marijuana-pregnant-preterm-birth-risk.html

“Marijuana Is Safe During pregnancy, Experts Do Not Encourage. Marijuana does not increase pregnancy risk according to new research. It does not have a negative outcome when it comes to premature birth and low birth weight. Still, experts do not encourage marijuana use during pregnancy.” http://www.scienceworldreport.com/articles/47194/20160910/marijuana-safe-during-pregnancy-experts-encourage.htm

Spontaneous involution of pediatric low-grade gliomas: high expression of cannabinoid receptor 1 (CNR1) at the time of diagnosis may indicate involvement of the endocannabinoid system.

Image result for Childs Nerv Syst

“Pediatric low-grade gliomas (P-LGG) consist of a mixed group of brain tumors that correspond to the majority of CNS tumors in children.

Notably, they may exhibit spontaneous involution after subtotal surgical removal (STR). In this study, we investigated molecular indicators of spontaneous involution in P-LGG.

CONCLUSIONS:

The P-LGG, which remained stable or that presented spontaneous involution after STR, showed significantly higher CNR1 expression at the time of diagnosis.

We hypothesize that high expression levels of CNR1 provide tumor susceptibility to the antitumor effects of circulating endocannabinoids like anandamide, resulting in tumor involution.

This corroborates with reports suggesting that CNR1 agonists and activators of the endocannabinoid system may represent therapeutic opportunities for children with LGG.

We also suggest that CNR1 may be a prognostic marker for P-LGG.

This is the first time spontaneous involution of P-LGG has been suggested to be induced by endocannabinoids.”

http://www.ncbi.nlm.nih.gov/pubmed/27613640

Cannabis for Cognitive Enhancement as a New Coping Strategy? Results From a Survey of Students at Four Universities in Germany.

Image result for substance use & misuse

“Cognitive Enhancement (CE) is often discussed in relation to stimulant drugs, such as amphetamines (AMPH).

However, there is some evidence that cannabis (CAN) can be used for CE.

A survey was taken of 1,538 students at four German universities.

A considerable number of students report having used CAN for CE.”

http://www.ncbi.nlm.nih.gov/pubmed/27607062

Activation of Cannabinoid Receptor 2 Ameliorates DSS-Induced Colitis through Inhibiting NLRP3 Inflammasome in Macrophages.

Image result for plos one logo

“Activation of cannabinoid receptor 2 (CB2R) ameliorates inflammation, but the underlying mechanism remains unclear.

In the present study, we examined whether activation of CB2R could suppress the nucleotide-binding domain and leucine-rich repeat protein 3 (NLRP3) inflammasome.

We conclude that activation of CB2R ameliorates DSS-induced colitis through enhancing autophagy that may inhibit NLRP3 inflammasome activation in macrophages.”

http://www.ncbi.nlm.nih.gov/pubmed/27611972